Pathophysiology

1. Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, ten Berge IJM. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct. 2016;2(1):e48.

2. Zimmermann H, Trappe RU. Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol. 2011;2(6):393-407.

3. Mrozek-Gorska P, Buschle A, Dagmar P, et al. Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc Natl Acad Sci U S A. 2019;116(32):16046-16055.

Unmet Need

1. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173-183.

2. Socié G, Pigneux A, Herbaux C, et al. Clinical outcomes of EBV⁺ PTLD patients following HCT who fail rituximab: a retrospective chart review study from France. Presented at: 46th Annual Meeting of the European Society for Blood and Marrow Transplantation; August 2020.

3. Zimmermann H, Xu H, Barlev A, et al. Clinical outcomes of solid organ transplant patients with EBV⁺ PTLD who fail first-line rituximab or rituximab plus chemotherapy: an analysis of German PTLD registry. Poster and abstract presented at: European Hematology Association 24th Annual Congress; June 13-16, 2019; Amsterdam, Netherlands.